10x Genomics Acquires Proteintech Genomics to Build Out Multi-Omics Spatial Biology Platform

The Quick Take

• 10x Genomics is acquiring Proteintech Genomics to add protein analysis to its spatial biology platform
• The acquisition moves 10x toward a comprehensive multi-omics platform combining RNA, DNA, and protein analysis
• Platform expansion strengthens 10x's competitive position against Illumina and Bruker in spatial biology

10x Genomics, the spatial biology and single-cell genomics platform company, is expanding its capabilities through the acquisition of Proteintech Genomics, adding protein analysis capabilities to its existing RNA and DNA spatial genomics portfolio. 10x Genomics has built a market-leading position in single-cell RNA sequencing and spatial transcriptomics — technologies that allow researchers to analyze gene expression at the individual cell level and within tissue contexts. The Proteintech Genomics acquisition adds a complementary protein-level analysis layer, moving 10x toward a more comprehensive multi-omics platform that can interrogate both genomic and proteomic data from the same biological samples.

The acquisition strengthens 10x Genomics' competitive position against Illumina's spatial biology initiatives, Bruker's spatial proteomics tools, and emerging competitors in the rapidly evolving single-cell and spatial biology market. Multi-omics platform integration is increasingly valued by pharmaceutical and biotech research customers, as simultaneous genomic and proteomic analysis from a single sample reduces experimental complexity, cost, and sample consumption. For institutional research customers including major cancer centers, pharmaceutical R&D organizations, and government-funded genomics programs, a more comprehensive 10x platform reduces the need for multi-vendor instrument workflows, increasing platform stickiness and reducing churn risk.

Watch for 10x Genomics' commercial integration timeline for Proteintech capabilities into its Chromium and Visium platforms, which will determine the speed of revenue uplift from existing customers upgrading their workflows. The company's next quarterly earnings will provide guidance on whether the acquisition is expected to be accretive or dilutive in the near term. The macro variable governing the spatial biology sector is NIH and government research funding: any changes to federal research budget allocation under the current administration directly affect the purchasing power of academic and government research customers that represent a significant portion of 10x Genomics' installed base.

Synthesized from 1 source.